Inclusion Criteria:

- Men and women with age ≥ 18 years

- Patient capable of giving informed consent and able to attend study visits

- Weight < 140kg

- Radiologic evidence of bone metastases from any solid tumor

- Diagnosis of dominant painful bone metastasis (Numerical Representative Scale (NRS)
pain score ≥4), either refractory to standard of care (including radiotherapy and
optimal pain medication) or standard of care is contra-indicated or refused by
patient.

- Patient has been on stable pain medication for at least 1 week prior to HIFU
treatment date

- Pain is localized to the targeted area, or is likely to be referred pain arising from
the targeted area

- Patient has 1-3 painful lesions, and only the most painful lesion will be treated

- Intended Target Volume accessible for MR-HIFU procedure

- Target lesion maximum dimension ≤ 8cm

- Intended target volume visible by non-contrast MRI

- Distance between target and skin ≥ 1cm

- Patient is able to communicate sensation during MR-HIFU treatment

- MR-HIFU treatment date ≥ 4 weeks from last local treatment of the target lesion

- MR-HIFU treatment date ≥ 4 weeks from participation in another clinical trial

Exclusion Criteria:

- Planned treatment lesion is a primary bone tumor or due to lymphoma, multiple
myeloma, or leukemia.

- Communication barrier present

- Unable to tolerate required stationary position during treatment

- Need for surgical stabilization in case of (impending) fracture (lytic lesion in
weight-bearing bone larger than 50% of bone diameter)

- Pregnant woman

- Pain related to target lesion is predominantly due to fracture or impending fracture

- Pain related to target lesion is due to involvement of a neighboring major nerve by
the metastatic tumor (cord or nerve compression)

- Target < 3cm from bladder / bowel / nerve along the beam path and < 1cm in the plane
orthogonal to the beam

- Target in contact with hollow viscera

- Target located in skull, joints, ribs (when HIFU beam overlapping with lung), spine
(excluding sacrum which is allowed) or sternum

- Scar along proposed HIFU beam path

- Internal or external fixation device along the proposed HIFU beam path or at the
target

- MRI contraindicated (e.g. paramagnetic implants, pacemaker, claustrophobia)

- MRI contrast agent contraindicated (e.g. previous anaphylaxis or Glomerular
Filtration Rate (GFR) < 30 ml/min/1.73m2)

- Sedation contraindicated

- Previous surgery or minimally invasive treatment at targeted site

- Clinically relevant medical history or abnormal physical findings that could
interfere with the safety of the participant as judged by the treating physician or
investigator